
Physician-reviewed TRT education
Yes, testosterone therapy can raise blood pressure in some men. The average increase may be modest, but FDA now requires blood-pressure warnings across testosterone products and recommends periodic monitoring.
Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

Testosterone therapy can increase blood pressure, and current FDA labeling treats this as a class-wide safety issue. In 2025, FDA required testosterone products to add or strengthen warnings about increased blood pressure after ambulatory blood-pressure studies showed increases across products.
At the same time, the large TRAVERSE trial did not show an increased rate of major adverse cardiovascular events with testosterone gel compared with placebo in appropriately selected men with hypogonadism and cardiovascular risk. Blood pressure and major cardiovascular events are related questions, but they are not the same question.
FDA reviewed postmarketing ambulatory blood-pressure monitoring studies and concluded that testosterone products can increase blood pressure. The agency required product-specific blood-pressure information and a new class-wide warning for products that did not already carry one.
Current testosterone labeling advises clinicians to measure blood pressure periodically and notes that testosterone products are not recommended for men with uncontrolled hypertension.
The amount varies by product and patient. In one ambulatory blood-pressure study of testosterone gel 1.62%, average 24-hour systolic blood pressure increased by about 1.9 mm Hg at 16 weeks. That average is small, but individual responses can be larger, especially in people who already have hypertension, diabetes or other cardiovascular risk factors.
This is why blood pressure should be followed rather than assumed to remain unchanged.
The TRAVERSE trial enrolled more than 5,000 men with hypogonadism and preexisting or elevated cardiovascular risk. Major adverse cardiovascular events occurred at similar rates in the testosterone and placebo groups, establishing noninferiority for the primary cardiovascular endpoint.
TRAVERSE did identify higher rates of some adverse events, including atrial fibrillation, acute kidney injury and pulmonary embolism, so the study should not be interpreted as proving that testosterone has no cardiovascular risks.
FDA subsequently removed the older boxed-warning language about increased major cardiovascular events while separately strengthening blood-pressure warnings.
For the wider evidence, read Is Long-Term Testosterone Therapy Safe? and our TRT evaluation and treatment guide.
The mechanism is probably multifactorial. Testosterone can influence sodium and fluid retention, vascular tone, sympathetic activity and red-blood-cell production. Different formulations may produce different peak concentrations and physiologic effects.
Blood pressure can also rise for reasons unrelated to testosterone, including weight gain, sleep apnea, alcohol use, kidney disease, stress, diet, medications and underlying essential hypertension.
Not necessarily. Testosterone can raise hemoglobin and hematocrit, and excessive erythrocytosis may contribute to cardiovascular risk, but blood-pressure changes can occur independently of hematocrit.
Both should be monitored. See our detailed guide to hematocrit on testosterone therapy.
Observational studies have sometimes found lower testosterone levels in men with hypertension, and some older physiologic studies suggested favorable vascular effects of testosterone. Those findings do not establish testosterone therapy as a treatment for high blood pressure.
TRT should not be prescribed to lower blood pressure. Hypertension should be evaluated and treated on its own merits.
Extra caution is appropriate in men with uncontrolled hypertension, significant cardiovascular disease, kidney disease, obstructive sleep apnea, obesity, diabetes, high hematocrit or multiple cardiovascular risk factors. These conditions do not automatically rule out TRT, but they increase the importance of appropriate evaluation and follow-up.
Blood pressure should be checked before treatment and periodically afterward. Home readings can be useful when obtained with a validated upper-arm cuff and proper technique.
If readings rise consistently after starting or changing testosterone, the clinician should review the dose, formulation, timing, weight, sleep apnea, fluid retention, other medications and overall cardiovascular risk rather than assuming the change is unrelated.
The correct response depends on severity. Options may include confirming the readings, addressing lifestyle contributors, treating hypertension, reducing testosterone exposure, changing the formulation or reassessing whether TRT remains appropriate.
Do not abruptly stop or change a prescription without discussing it with the prescriber unless urgent medical care is needed.
Supraphysiologic testosterone exposure can increase adverse effects and is not the goal of replacement therapy. The safest approach is an individualized dose that achieves appropriate physiologic levels and symptom benefit without unnecessary exposure.
See our guide to normal TRT dosing.
It can contribute to higher blood pressure in some men. Whether it causes persistent hypertension depends on the individual and other risk factors.
Not automatically. Confirm the readings and contact the prescribing clinician. A treatment adjustment or separate hypertension treatment may be appropriate.
It may be appropriate when hypertension is controlled and the overall risk-benefit assessment supports treatment. Current labeling advises against testosterone use in men with uncontrolled hypertension.
FDA considers increased blood pressure a class-wide testosterone risk, so injectable products are included. The degree of change varies between patients.
There is no single universal cutoff in TRT guidelines that applies to every clinical situation, but uncontrolled hypertension should be addressed before or during therapy. Urgent or severely elevated readings require prompt medical evaluation regardless of TRT status.
NovaGenix can review blood-pressure readings, testosterone dose, CBC/hematocrit, current medications and cardiovascular risk factors as part of a physician-led TRT follow-up. Learn more about Dr. Timothy Mackey and NovaGenix Health & Wellness.
Call 561-277-8260 | Text NovaGenix | Schedule a Consultation
This article is educational and does not replace individualized medical advice. Seek urgent medical care for severely elevated blood pressure or symptoms such as chest pain, severe shortness of breath, neurologic deficits or other emergencies.
Speak with NovaGenix about physician-led evaluation, testing, and treatment options in Jupiter, Florida.
Medical disclaimer: This article is for general educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Reading it does not create a physician-patient relationship. Always consult a qualified healthcare professional about your individual circumstances, and never delay seeking care because of something you read here. If you are experiencing a medical emergency, call 911. Read our full Medical Disclaimer.


609 N Hepburn avenue suite 106. Jupiter, Florida 33458
609 N Hepburn avenue suite 106. Jupiter, Florida 33458
561-277-8260
Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed